Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.
Research article published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013)
Abstract
PURPOSE: To develop an evidence-based guideline on central venous catheter (CVC) care for patients with cancer that addresses catheter type, insertion site, and placement as well as prophylaxis and management of both catheter-related infection and thrombosis. METHODS: A systematic search of MEDLINE and the Cochrane Library (1980 to July 2012) identified relevant articles published in English. RESULTS: The overall quality of the randomized controlled trial evidence was rated as good. There is consistency among meta-analyses and guidelines compiled by other groups as well. RECOMMENDATIONS: There is insufficient evidence to recommend one CVC type or insertion site; femoral catheterization should be avoided. CVC should be placed by well-trained providers, and the use of a CVC clinical care bundle is recommended. The use of antimicrobial/antiseptic-impregnated and/or heparin-impregnated CVCs is recommended to decrease the risk of catheter-related infections for short-term CVCs, particularly in high-risk groups; more research is needed. The prophylactic use of systemic antibiotics is not recommended before insertion. Data are not sufficient to recommend for or against routine use of antibiotic flush/lock therapy; more research is needed. Before starting antibiotic therapy, cultures should be obtained. Some life-threatening infections require immediate catheter removal, but most can be treated with antimicrobial therapy while the CVC remains in place. Routine flushing with saline is recommended. Prophylactic use of warfarin or low-molecular weight heparin is not recommended, although a tissue plasminogen activator (t-PA) is recommended to restore patency to occluded catheters. CVC removal is recommended when the catheter is no longer needed or if there is a radiologically confirmed thrombosis that worsens despite anticoagulation therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
To develop an evidence-based guideline on central venous catheter (CVC) care for patients with cancer that addresses catheter type, insertion site, and placement as well as prophylaxis and management of both catheter-related infection and thrombosis. A systematic search of MEDLINE and the Cochrane...
Warum dies für die Hirudotherapie relevant ist
Dieser Artikel stellt eine evidenzbasierte Leitlinie zur Versorgung zentralvenöser Katheter bei onkologischen Patienten vor und behandelt Kathetertyp, Insertionsstelle, Platzierung sowie Prophylaxe und Management katheterassoziierter Infektionen und Thrombosen. Die Empfehlungen umfassen die Verwendung von Versorgungsbündeln (Care Bundles), antimikrobiell oder heparinbeschichteten Kathetern für den kurzfristigen Gebrauch bei Hochrisikogruppen, routinemäßige Spülung mit Kochsalzlösung und t-PA zur Wiederherstellung der Durchgängigkeit verschlossener Katheter; prophylaktisches Warfarin oder niedermolekulares Heparin wird nicht empfohlen. Für ASHs Fachgebiet ist jegliche Relevanz auf den allgemeinen klinischen Kontext der Antikoagulanzienanwendung bei Gefäßzugangssystemen beschränkt. Das Abstract erwähnt weder Blutegel, Hirudotherapie noch das Blutegel-Sekretom, sodass keine vertretbare blutegelspezifische Verbindung zum Fachgebiet der ASH hergestellt werden kann.
Zitation
Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.
Schiffer et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026